GET DAILY SIGNALSNovoCure (NVCR) Analysts Point to $25 Target, Implying +88% Upside From Recent Levels
Key Takeaways
- The central target used here is $25, the arithmetic mean of seven verified analyst price targets ranging from roughly $15 to $52.
- At a recent price near $13.28, reaching $25 would require a gain of about 88% — a very large move by any standard.
- The bullish case rests on record revenue, a first-ever positive adjusted EBITDA quarter, and raised 2026 guidance.
- The bearish case centers on continued GAAP losses, a slower U.S. launch of Optune Pax, and a wide analyst range that signals genuine uncertainty.
- For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
- Explore Trending AI Robots to see AI-driven trading strategies across the broader market.
Analyst Price Targets and Consensus View
NovoCure Limited (NVCR) is an oncology company that develops and commercializes Tumor Treating Fields (TTFields) devices used to treat solid-tumor cancers. It is a stock, not an exchange-traded fund, so the central target is built directly from sell-side analyst price targets.
Seven current, individually attributable targets were reviewed, producing a range of roughly $15 to $52. The arithmetic mean works out to about $25.29, rounded to a clean $25. That spread is unusually wide — the difference between the lowest and highest targets is more than threefold — which reflects sharply different assumptions about how quickly new products can scale.
Recent actions illustrate the split. Wells Fargo lowered its target from $20 to $15 and reiterated a Hold in late October, while Evercore ISI trimmed its target from $23 to $20 but kept a Buy. Piper Sandler maintained a $29 target, and H.C. Wainwright has been the most aggressive at $52. Wedbush sits in the middle at $20 with a Hold. There are no Sell ratings among the group, but the concentration of cautious Holds alongside wide-ranging Buys means the "consensus" is better described as constructive-but-uncertain than uniformly bullish.
Current Market Position and Path Toward the Target
NovoCure shares traded near $13.28 in early November 2026, well off the 52-week high of $21.45 and closer to the 52-week low of $9.82. Moving to $25 would require an advance of roughly 88%, which qualifies as a very large move rather than a modest or routine one.
The path would likely depend on execution rather than a single event. NovoCure reported record third-quarter 2026 net revenue of about $193 million, up 16% year over year, and posted positive adjusted EBITDA of roughly $16 million for the first time in years. Management raised full-year 2026 revenue guidance to $736–$743 million and adjusted EBITDA guidance to $24–$34 million. Yet the company still reported a GAAP net loss of about $10 million, and fourth-quarter revenue guidance implies a sequential step down from the third quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Could Support a Move Toward the Target
Several verified developments underpin the bullish case. Active patients grew 19% year over year, and the core Optune Gio glioblastoma franchise posted record active-patient counts. The company is also expanding into new markets: Optune Lua (lung cancer) is generating revenue in Japan, and Optune Pax (pancreatic cancer) is launching, albeit slowly in the U.S. A balance sheet with roughly $463 million in cash and investments provides runway to fund launches and clinical programs without immediate financing pressure. Gross margin improved to 77%, and management signaled continued progress toward cash-flow breakeven.
What Could Prevent the Target From Being Reached
The principal obstacles are equally concrete. NovoCure remains unprofitable on a GAAP basis, and its fourth-quarter revenue guide points to a sequential decline tied partly to one-time benefits that will not repeat. The U.S. launch of Optune Pax has been disrupted by competition from a rival therapy, daraxonrasib, which has limited access to physician practices. Reimbursement and contracting hurdles in Europe and Japan can delay revenue realization. Finally, the enormous dispersion in analyst targets — from $15 to $52 — is itself a warning that the company's long-term earnings power is not yet firmly established in the market's view.
Technical Levels and Market Structure
From a technical standpoint, the stock is trading below both its 50-day moving average (near $15.40) and its 200-day moving average (near $14.82), indicating near-term downward pressure. The $15 area also coincides with the low end of the analyst range and represents an early resistance level to reclaim. The 52-week high near $21.45 is the next major hurdle above that, while $9.82 marks key downside support.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though firms differ and none of these figures should be read as a guarantee. Key items to watch include quarterly revenue and active-patient trends, the ramp of Optune Lua in Japan and Optune Pax in the U.S., progress on the LUNAR-2 and PANOVA clinical programs, reimbursement decisions in major markets, and whether adjusted EBITDA continues to expand toward the company's stated goal of cash-flow breakeven. Analyst revisions following each earnings print will also matter, given how quickly targets have shifted this year. From what I see, tracking these elements closely helps clarify the path forward.
AI Daily Buy/Sell Signals
Investors tracking a stock with this much volatility may benefit from systematic tools such as Tickeron's AI Daily Buy/Sell Signals. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Rather than replacing fundamental research, it helps traders surface opportunities, monitor existing positions, and spot changing trends more efficiently. Consider exploring the signals to complement your own due diligence on NVCR.
Final Assessment
The $25 target is not a forecast; it is the arithmetic mean of seven analyst price targets spanning roughly $15 to $52. Reaching it from near $13.28 would require about an 88% advance — a very large move that hinges on NovoCure converting its improving fundamentals, including record revenue and positive adjusted EBITDA, into sustained profitable growth while overcoming the slow U.S. Optune Pax launch and persistent GAAP losses. The wide analyst range shows how much disagreement exists about the speed of that transition. Investors should focus on revenue trajectory, patient growth, new-product ramps, and cash-flow progress rather than any single price level.
Exploring Tickeron AI Tools
I have found Tickeron’s AI Daily Buy/Sell Signals particularly useful for monitoring volatile names like this one. The platform applies AI to scan market data in real time and flag potential shifts, which can serve as a helpful complement to traditional analysis when evaluating execution risks and timing around earnings or product launches. It is one of several resources I turn to when building a fuller picture of opportunity and downside.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NVCR sees MACD Histogram crosses below signal line
NVCR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 29, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 42 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVCR as a result. In 70 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NVCR entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NVCR's RSI Oscillator exited the oversold zone, 21 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 64 cases where NVCR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
Following a +10.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCR advanced for three days, in 205 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
NVCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. NVCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.574) is normal, around the industry mean (4.142). P/E Ratio (-10.215) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (40.950) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a commercial-stage oncology company
Industry MedicalNursingServices
Advertisement